doi: 10.1016/0014-2999(92)90634-g.
The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way
Affiliations
- PMID: 1618282
- DOI: 10.1016/0014-2999(92)90634-g
Item in Clipboard
The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way
Eur J Pharmacol.
.
Abstract
The anti-viral drug amantadine is used in the treatment of Parkinson's disease without the drug having a well established mechanism of action. Amantadine is reported to displace the non-competitive NMDA receptor antagonist MK-801 from its binding site in the central nervous system. We show that amantadine inhibits, in a non-competitive way, the NMDA receptor-mediated stimulation of acetylcholine release from rat neostriatum in vitro in 'therapeutic' (i.e. low micromolar range) concentrations. Moreover, contrary to previous reports, amantadine, in this concentration range, did not affect the in vitro release of dopamine from neostriatal tissue.
Similar articles
-
Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications?Clin Neurol Neurosurg. 1992;94 Suppl:S4-6. doi: 10.1016/0303-8467(92)90006-o. Clin Neurol Neurosurg. 1992. PMID: 1320514
-
Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro.J Pharmacol Exp Ther. 1992 Nov;263(2):717-24. J Pharmacol Exp Ther. 1992. PMID: 1359111
-
Differences in the regulation of acetylcholine release upon D2 dopamine and N-methyl-D-aspartate receptor activation between the striatal complex of reptiles and the neostriatum of rats.Brain Res. 1991 Dec 6;566(1-2):8-12. doi: 10.1016/0006-8993(91)91674-p. Brain Res. 1991. PMID: 1687666
-
Role of arachidonic acid in the regulation of the NMDA-evoked release of acetylcholine in striatal compartments.Synapse. 1999 Feb;31(2):140-50. doi: 10.1002/(SICI)1098-2396(199902)31:2<140::AID-SYN7>3.0.CO;2-2. Synapse. 1999. PMID: 10024011
-
Depression of NMDA-evoked acetylcholine release by endogenous adenosine in striatum slices.Adv Exp Med Biol. 1991;287:241-8. doi: 10.1007/978-1-4684-5907-4_20. Adv Exp Med Biol. 1991. PMID: 1759610
Cited by
-
Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials.J Neural Transm (Vienna). 2021 Feb;128(2):127-169. doi: 10.1007/s00702-021-02306-2. Epub 2021 Feb 23. J Neural Transm (Vienna). 2021. PMID: 33624170 Free PMC article. Review.
-
Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study.J Neurol. 1996 May;243(5):422-5. doi: 10.1007/BF00869004. J Neurol. 1996. PMID: 8741085 No abstract available.
-
Direct inhibition of the N-methyl-D-aspartate receptor channel by dopamine and (+)-SKF38393.Br J Pharmacol. 1999 Apr;126(8):1847-55. doi: 10.1038/sj.bjp.0702479. Br J Pharmacol. 1999. PMID: 10372829 Free PMC article.
-
Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia.J Neural Transm (Vienna). 2018 Aug;125(8):1237-1250. doi: 10.1007/s00702-018-1869-1. Epub 2018 Mar 7. J Neural Transm (Vienna). 2018. PMID: 29511826 Review.
-
Amantadine-induced patulous eustachian tubes in Parkinson's disease.Case Rep Otolaryngol. 2013;2013:426413. doi: 10.1155/2013/426413. Epub 2013 Nov 20. Case Rep Otolaryngol. 2013. PMID: 24349813 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
